Urica Therapeutics, a Fortress Biotech (FBIO) subsidiary, announced that Crystalys Therapeutics, in which Urica maintains an equity position, dosed first patients in its two randomized, double-blind, multicenter global Phase 3 trials, the RUBY study and the TOPAZ study, evaluating dotinurad, a next-generation, once daily oral, URAT1 inhibitor with potential for best-in-class safety and efficacy for the treatment of gout.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FBIO:
- Largest borrow rate increases among liquid names
- Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!
- Fortress Biotech: Buy Rating Affirmed Amid Strategic Developments and Financial Upside
- Fortress Biotech Receives FDA Response on CUTX-101
- Why Is Fortress Biotech Stock (FBIO) Down 30% Today?